Response to highly active antiretroviral therapy according to duration of HIV infection

被引:0
|
作者
Pezzotti, P
Pappagallo, M
Phillips, PN
Boros, S
Valdarchi, C
Sinicco, A
Zaccarelli, M
Rezza, G
机构
[1] Ist Super Sanita, Reparto AIDS & MST, I-00161 Rome, Italy
[2] UCL Royal Free & Univ Coll Med Sch, London, England
[3] Univ Turin, Turin, Italy
[4] IRCCS L Spallanzani, Rome, Italy
关键词
antiretroviral therapy; HIV seroconverters; effectiveness; cohort study;
D O I
暂无
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Objective: To evaluate whether duration of HIV-1 infection influences the response to highly active antiretroviral therapy (HAART). Design: Prospective study of individuals (Italian Seroconversion Study cohort) with well-estimated dates of HIV-1 seroconversion. Methods: This analysis included 277 participants who began HAART (defined as three antiretroviral drugs used in combination). Cox regression models were used to evaluate the association between duration of infection (as categorical variable [less than or equal to3, 3-7.5, >7.5 years from seroconversion] or continuous variable) and an immunologic (rise in CD4 count >100 cells/mm(3)) and a virologic (decline in plasma HIV-RNA to unquantifiable levels) outcome. All analyses were stratified by center of recruitment and adjustment, when used, was for gender, age at inception of HAART, injection drug use. previous antiretroviral therapy, lag-time between positive and negative HIV test result, year of starting HAART, clinical stage, CD4 count, and HIV-RNA at time of HAART. Results: HAART was initiated a median of 6.4 years after seroconversion, There was a median follow-up of 1.6 years after starting HAART to the calendar cut-off (November 1999). One-hundred-eighty-one (65.3%) patients experienced a decline in viral load to below quantifiable levels and 184 (66.4%) experienced a rise in CD4 >100 cells/mm(3). In the Cox models, by 1-year increase in duration of infection, we estimated a lower crude hazard of achieving a CD4 count increase >100 cells (relative hazard [RH], 0.96: 95% confidence interval [CI]. 0.92-1.01; p = .09), and a lower hazard of reaching an unquantifiable level of plasma HIV-RNA (RH, 0.97; 95%CI, 0.93-1.02; p = .20). After adjustment, these values became 0.99 (95%CI, 0.93-1.04; p = .62) and 0.98 (95%CI, 0.93-1.03; p = .48), respectively. When duration of HIV infection was considered as a categorical variable, the results were consistent with those already described. Conclusions: These results suggest that the duration of HIV infection does not seem to play an important independent role in determining the virologic and immunologic responses to HAART.
引用
收藏
页码:473 / 479
页数:7
相关论文
共 50 条
  • [21] Disseminated rhodococcus equi infection in HIV infection despite highly active antiretroviral therapy
    Francesca Ferretti
    Antonio Boschini
    Cristiana Iabichino
    Simonetta Gerevini
    Paola De Nardi
    Monica Guffanti
    Giuseppe Balconi
    Adriano Lazzarin
    Paola Cinque
    BMC Infectious Diseases, 11
  • [22] Disseminated Rhodococcus equi infection in HIV infection despite highly active antiretroviral therapy
    Ferretti, Francesca
    Boschini, Antonio
    Iabichino, Cristiana
    Gerevini, Simonetta
    De Nardi, Paola
    Guffanti, Monica
    Balconi, Giuseppe
    Lazzarin, Adriano
    Cinque, Paola
    BMC INFECTIOUS DISEASES, 2011, 11
  • [23] Clinical outcome of patients with HIV-1 infection according to immunologic and virologic response after 6 months of highly active antiretroviral therapy
    Grabar, S
    Le Moing, V
    Goujard, C
    Leport, C
    Kazatchkine, MD
    Costagliola, D
    Weiss, L
    ANNALS OF INTERNAL MEDICINE, 2000, 133 (06) : 401 - 410
  • [24] Immunological response to highly active antiretroviral therapy in children with clinically stable HIV-1 infection
    Rosenblatt, HM
    Stanley, KE
    Song, LY
    Johnson, GM
    Wiznia, AA
    Nachman, SA
    Krogstad, PA
    JOURNAL OF INFECTIOUS DISEASES, 2005, 192 (03): : 445 - 455
  • [25] Highly active antiretroviral therapy and HIV transmission
    Montaner, Julio
    LANCET, 2006, 368 (9548): : 1647 - 1647
  • [26] Intensive care in patients with HIV infection in the era of highly active antiretroviral therapy
    Narasimhan, M
    Posner, AJ
    DePalo, VA
    Mayo, PH
    Rosen, MJ
    CHEST, 2004, 125 (05) : 1800 - 1804
  • [27] HIV Infection and Survival of Lymphoma Patients in the Era of Highly Active Antiretroviral Therapy
    Han, Xuesong
    Jemal, Ahmedin
    Hulland, Erin
    Simard, Edgar P.
    Nastoupil, Loretta
    Ward, Elizabeth
    Flowers, Christopher R.
    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2017, 26 (03) : 303 - 311
  • [28] Intracranial aneurysm revealing a HIV infection and resolving with highly active antiretroviral therapy
    Benjilali, Laila
    Zahlane, Mouna
    Essaadouni, Lamiaa
    NEUROLOGY INDIA, 2012, 60 (03) : 351 - U104
  • [29] Antitissue transglutaminase antibodies in HIV infection and effect of highly active antiretroviral therapy
    Pereda, I
    Bartolomé-Pacheco, MJ
    Martín, M
    López-Escribano, H
    Echevarría, S
    López-Hoyos, M
    JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2001, 27 (05) : 507 - 508
  • [30] Effect of highly active antiretroviral therapy and thymic transplantation on immunoreconstitution in HIV infection
    Markert, ML
    Hicks, CB
    Bartlett, JA
    Harmon, JL
    Hale, LP
    Greenberg, ML
    Ferrari, G
    Ottinger, J
    Boeck, A
    Kloster, AL
    McLaughlin, TM
    Bleich, KB
    Ungerleider, RM
    Lyerly, HK
    Wilkinson, WE
    Rousseau, FS
    Heath-Chiozzi, ME
    Leonard, JM
    Haase, AT
    Shaw, GM
    Bucy, RP
    Douek, DC
    Koup, RA
    Haynes, BF
    Bolognesi, DP
    Weinhold, KJ
    AIDS RESEARCH AND HUMAN RETROVIRUSES, 2000, 16 (05) : 403 - 413